Scientific Program

PDF PROGRAM
Friday, 25 September 2026
13:30-14:00 Opening & Introduction
  Welcome Speech by Organizing Committee Serkan Özben
Jelena Drulović
Murat Terzi
     
14:00-15:10 Session 1: Early and Prodromal Parkinson's Disease
  Chairs: Ayşe Bora Tokçaer, Raif Çakmur, Serkan Özben
14:00-14:20 Parkinson’s Disease: Molecular Pathology, Clinical Implications and Recent Advances Bülent Elibol
14:20-14:40 Differential Diagnosis in Parkinsonism Serhat Özkan
14:40-15:00 Non-motor symptoms in Parkinson disease-Impact on the disease course and treatment Nataša Dragašević
15:00-15:10 Questions & Answers  
15:10-15:30 COFFEE BREAK  
15:30-16:55 Session 2: Advanced and Device-Aided Therapies in Parkinson's Disease
  Chairs: Dimitar Maslarov, Nataša Dragašević, Okan Doğu
15:30-15:45 Infusion Therapies: Where Do We Stand in 2026? Nevena Kamenova
15:45-16:00 Deep Brain Stimulation in Parkinson's Disease: Patient Selection and Long-Term Outcomes Gençer Genç
16:00-16:15 Deep Brain Stimulation in Dystonia Vladana Marković
16:15-16:30 The Next Frontier in Parkinson’s Interventions:  From Natural History to AI-Driven Adaptive Neuromodulation Dimitar Maslarov
16:30-16:45 Impulse Control Disorders in Parkinson's Disease: Clinical Implications and Management Strategies Igor Petrović
16:45-16:55 Questions & Answers  
16:55-17:35 Session 3: Parkinson's Disease: Panel Discussion & Rapid-Fire Questions
  Chairs: Bülent Elibol, Igor Petrović, Ivan Milanov Panelists: 
  Moderator: Bülent Elibol Andona Milovanović
Ayşegül Gündüz
Desislava Bogdanova
Gençer Genç
Haşmet Hanağası
Maksim Šarčević
Nina Mazalica
  Session Fellows: Ahmet Onur Keskin, Gözde Ünal
17:35-18:50 Abstract Sessions: Oral Presentations
  Chairs: Sibel Canbaz Kabay, Şeyda Figül Gökçe Hall 1
 
17:35 - 17:42 SS - 001 Assessing Walking Under Cognitive Demands in Multiple Sclerosis: Psychometric Properties of the Trail Walking Test Ahmet Onur Keskin
17:42 - 17:49 SS - 002 Pregnancy outcomes in multiple sclerosis patients treated with natalizumab - Real world data Marta Jeremić
17:49 - 17:56 SS - 003 CYP2C9 Pharmacogenetic Screening Prior to Siponimod Treatment in Serbian Patients with Secondary Progressive Multiple Sclerosis Milena Jankovic
17:56 - 18:03 SS - 004 Lower Baseline Brodmann Area 35 Morphometry Is Associated With Faster Clinical Progression In Mild Cognitive Impairment Aslı Aksoy Gündoğdu
18:03 - 18:10 SS - 005 Impact of type 2 diabetes comorbidity on disability progression in multiple sclerosis Gorica Maric
18:10 - 18:17 SS - 006 Antipsychotic Use in Patients Receiving Subthalamic Nucleus Deep Brain Stimulation (STN-DBS): A Single-Center Experience Mehmet Orçun Solak
18:17 - 18:24 SS - 007 Clinical Correlates and Machine-Learning Classification of Hallucinations in Parkinson’s Disease: A Preliminary Evaluation of the Serbian Version of the Tottori University Hallucination Rating Scale Nina Mazalica
18:24 - 18:31 SS - 008 Problematic internet use in Parkinson's disease: clinical and behavioral predictors Nina Mazalica
18:32 - 18:39 SS - 017 Neurofilaments in serum as diagnostic and prognostic biomarkers in patients with amyotrophic lateral sclerosis Aleksa Palibrk
18:40 - 18:47 SS - 018 Different Paths, Different Outcomes: Longitudinal Clinical Trajectories and Survival in Parkinson’s Disease Maksim Šarčević
  Abstract Sessions: Poster Presentations
17:35-18:35 Chairs:Ufuk Emre Toprak, Yusuf Tamam Foyer
 
PS-001 A Silent Threat Mimicking Stroke: Cerebral Venous Sinus Thrombosis Secondary to Chronic Otitis Media Ufuk Emre Toprak
PS-002 {PRKN}-Linked Parkinsonism: Diagnostic Insights from Clinical Exome Sequencing Milena Bascarevic
PS-008 Gender differences in long-term survival of patients with Parkinson's disease Miloš Drljača
PS-009 Long-term prognosis and dynamics of impulse control disorders in patients with Parkinson’s disease Maksim Šarčević
Saturday, 26 September 2026
08:30-09:20 Breakfast with the Professors
 

Hüsnü Efendi - Šarlota Mesaroš - Nilüfer Kale İçen - Jasna Jančić - Aslı Aksoy Gündoğdu - Gökçen Gözübatık Çelik - Özlem Ethemoğlu - Rabia Koç

Bülent Elibol - Enra Mehmedica Suljić - Liljana Radulović - Evica Dinčić- Lorand Sakalas - Marko Andabaka - Ayça Gül Güngördü - Haluk Gümüş

Ayşe Altıntaş - Ivan Milanov - Nikola Momčilović - Aleksandar Pantović - Sedat Şen - Meral Seferoğlu - Coşkun Kerala

Jelena Drulović - Rana Karabudak - Tatjana Petkovska Boshkova - Dejan Aleksić - Marta Jeremić - Dr. Hamza Jatić - Mehmet Fatih Yetkin- Sami Ömer Hoca

09:30-10:40 Session 4: Redefining Alzheimer's Disease: From Biology to Clinical Practice
  Chairs: Haşmet Hanağası, Latchezar Traykov, Tanja Stojković
09:30-09:50 Is Alzheimer’s a Clinical Syndrome or a Biological Entity? Elka Stefanova
09:50-10:10 Blood-Based Biomarkers in Early Alzheimer's Disease: Where Do We Stand in 2026? Başar Bilgiç
10:10-10:30 Novel and future treatments of Alzheimer's disease Haşmet Hanağası
10:30-10:40 Questions & Answers  
10:40-11:00 COFFEE BREAK  
11:00-12:10 Session 5: Preventing Alzheimer's Disease: From Risk Reduction to Early Intervention
  Chairs: Elka Stefanova, Esen Saka Topçuoğlu, Shima Mehrabian
11:00-11:15 Prevention Strategies in Alzheimer's Disease: Lifestyle, Pharmacology, and Combination Approaches Tanja Stojković
11:15-11:30 Malnutrition in Dementia and Other Neurodegenerative Disorders Nazlı Durmaz Çelik
11:30-11:45 Artificial Intelligence in Alzheimer's Disease: From Early Detection to Treatment Monitoring Erdi Şahin
11:45-12:00 Risks, Benefits and Challenges of Early Detection for Pre-Dementia Alzheimer's Disease Shima Mehrabian
12:00-12:10 Questions & Answers  
12:10-12:40 Session 6: Alzheimer's Disease: Panel Discussion & Rapid-Fire Questions  
  Chairs: Başar Bilgiç, Elka Stefanova, Latchezar Traykov Panelists:
  Moderator: Başar Bilgiç
Session Fellows: Esra Acıman, Zeynep Özözen Ayas 		Erdi Şahin
Gorana Mandić
Nazlı Durmaz Çelik
Shima Mehrabian
Tanja Stojkovć
12:40-13:50 LUNCH BREAK  
13:50-14:30 INDUSTRY SUPPORTED SESSION  
14:30-16:00 Session 7: Brain Health in Multiple Sclerosis: From Care Models to Long-Term Outcomes  
  Chairs: Hüsnü Efendi, Mesrure Köseoğlu, Uğur Uygunoğlu  
14:30-14:50 Importance of MS units in Neurology Department Jelena Drulović
14:50-15:10 Unveiling PIRA: The Silent Driver of Neurodegeneration in Multiple Sclerosis Murat Kürtüncü
15:10-15:30 An overview: How changing immunological paradigms impacted our current treatment approaches   Rana Karabudak
15:30-15:50 Where Does IVIg Fit in the Era of Targeted Immunotherapies? Arman Çakar
15:50-16:00 Questions & Answers  
16:00-16:20 COFFEE BREAK  
16:20-17:40 Session 8:Preventing Neurodegeneration in MS: Clinical Decisions in the High-Efficacy Era  
  Chairs: Aysun Ünal, Tatjana Petkovska Boskova, Yeşim Beckman   
16:20-16:40 Neurodegenerative Mechanisms in Immune-Mediated CNS Disorders Erdem Tüzün
16:40-17:00 Pediatric-Onset MS: Preserving Brain Reserve from Disease Onset Paulina Ilieva
Late-Onset MS: Aging, Neurodegeneration and Therapeutic Challenges Mihaela Sergeeva
17:00-17:20 Escalation, Switching and Disease Control in Modern MS Care Sonya Ivanova 
De-escalation and Treatment Discontinuation: Protecting Brain Health in Aging MS Šarlota Mesaroš
17:20-17:30 Social Value of Early High-Effcacy Treatments Serkan Demir
17:30-17:40 Questions & Answers  
17:40-18:10 Session 9: Multiple Sclerosis:  Panel Discussion & Rapid-Fire Questions  
  Chairs: Ljiljana Radulović, Rana Karabudak, Slobodan Vojinović Panelists
  Moderator: Aslı Tuncer
Session Fellows: Mehmet Demir, Keriman Oğuz		 Cihat Uzunköprü
Maja Budimkić
Olivera Tamaš
Sonya Ivanova
Tuncay Gündüz
Vesna Suknjaja
Sunday, 27 September 2026
09:00-10:04 Abstract Sessions: Oral Presentations
  Chairs: Bengü Altunan, Mehmet Demir Hall 1
 
09:00 - 09:07 SS - 009 An undervalued symptom in Parkinson Disease: Sialorrhea Zeynep Özözen Ayas
09:07 - 09:14 SS - 010 AI-Assisted Smartphone Sensor-Based Gait and Turning Analysis in Parkinson’s Disease - A Pilot Study Muhammed Said Yıldırım
09:14 - 09:21 SS - 011 Short-Term Relapse Activity Following COVID-19 Infection and Vaccination in Multiple Sclerosis: A Self-Controlled Analysis Keriman Oğuz
09:21 - 09:28 SS - 012 Visual Evoked Potential Asymmetry and Systemic Inflammatory Indices in Active Versus Stable Multiple Sclerosis Batuhan Balık
09:28 - 09:35 SS - 013 Forward–Backward Digit Span Discrepancy Across Mild Cognitive Impairment and Dementia Subtypes: Associations With Clinical Severity, Medial Temporal Atrophy, and White Matter Hyperintensity Burden Onur Koç
09:35 - 09:42 SS - 014 Systemic Inflammatory Indices, Cerebral White Matter Hyperintensities, Medial Temporal Atrophy, And Cognition In Alzheimer’s Disease Oğuz Enes Şahin
09:42 - 09:49 SS - 015 Familial and Sporadic Essential Tremor: Clinical Features and Initial Treatment Response in a Single-Center Retrospective Study Soner Yağmur
09:49 - 09:56 SS - 016 Association of Inflammatory and Lipid Biomarkers with MRI phenotypes (atrophy and siderosis) in Cerebral Amyloid Angiopathy Elif Altin
09:57 - 10:04 SS - 019 Progressive supranuclear palsy: sex-based differences in clinical characteristics Miloš Drljača
09:00-10:00 Abstract Sessions: Poster Presentations
  Chairs: Tahir Kurtuluş Yoldaş, Ufuk Aluçlu Foyer
 
PS-003 Coexisting {PSEN1}-related early-onset Alzheimer’s disease and CNS demyelination: a case report Lenka Stojadinovic
PS-004 Leptomeningeal Carcinomatosis Presenting with Multiple Cranial Neuropathies in a Patient with Colorectal Cancer: A Case Report Yusuf Can Çelik
PS-006 Gait Metrics Predict 10-year Functional Independence in Early Parkinson’s Disease Una Lazic
PS-007 Baseline Predictors of Survival in Patients with Parkinson's Disease: a 10-year Longitudinal Cohort Study Una Lazic
  Chairs: Saltanat Mert, Zeynep Özdemir Foyer
 
PS-005 Polyneuropathy and Rheumatologic Diseases: A Report of Two Cases Ufuk Emre Toprak
PS-010 Early Versus Late Ocrelizumab Initiation in Relapsing-Remitting Multiple Sclerosis: A Retrospective, Multicenter Cohort Study Serkan Demir
PS-011 Therapeutic Inertia in Relapsing-Onset Multiple Sclerosis: A Real-World Registry Analysis of Treatment Escalation After Disease Activity Mehmet Fatih Yetkin
10:00-11:10 Session 10: Autoimmune Demyelinating Diseases: Biomarkers, Disability Prevention and Precision Therapies
  Chairs: Ayşe Altıntaş, Šarlota Mesaroš  
10:00-10:20 NMOSD vs MOGAD: Distinguishing Phenotypes and Biomarkers in Clinical Practice Ivan Milanov
10:20-10:40 Precision Treatment in NMOSD: Matching the Right Therapy to the Right Patient Nikola Veselinović
10:40-11:00: Vaccination Strategies in Patients Receiving Targeted Immunotherapies Tatjana Pekmezović
11:00-11:10 Questions & Answers  
11:10-12:40 Session 11: Motor Neuron Diseases: From Genetics to Disease Modification
  Chairs: Aleksa Palibrk, Zorica Stević  
11:10-11:30 ALS Genetics: From Risk Genes to Precision Medicine Ana Marjanović
11:30-11:50 ALS Motor Phenotypes: Upper vs Lower Motor Neuron Involvement and New Classification Zorica Stević
11:50-12:10 Diagnostic Strategies and Treatment Options in ALS Sezin Alpaydın Baslo
12:10-12:30 SMA in the Treatment Era: Long-Term Outcomes and New Challenges Nataša Cerovac
12:30-12:40 Questions & Answers  
12:40-13:00 Closing Remarks & Future Collaborations
  Closing Speech by Organizing Committee Aysun Ünal
Mesrure Köseoğlu
Serkan Özben